▟ Vinebot intrinsic value, daily

← back

MRK Merck & Co.

pharma · valued with opus medium conviction · deep-dived 2026-11-20

HOLD
Intrinsic value$81.41
Price (at call)$132.81
Margin of safety -38.7%
vs market (rating basis) -15.2%

Charge-depressed earnings hide a solid franchise, but the price still assumes the Keytruda handoff goes smoothly.

The story

Merck is a scaled, cash-rich pharma whose earnings still lean heavily on Keytruda, which faces US exclusivity loss around 2028. Subcutaneous Keytruda (Qlex), Winrevair, Capvaxive, and bought-in assets such as Ohtuvayre (Verona) and Cidara's flu antiviral are meant to bridge the cliff, and Gardasil's China weakness is a known drag. It is a mature franchise that must replace a giant, using acquisitions as R&D.

I kept all drivers unchanged. The TTM operating margin of about 10% comes from one-time acquired IPR&D charges on the Verona and Cidara deals and does not reflect a change in operating economics, so I still normalize to 33% over 3 years. Revenue is growing about 3.6%, which supports 4% in year 1. The TTM sales-to-capital of 0.66 is low because of those acquisitions, and I treat 1.0 as the sustainable blend of internal R&D plus business development spending over a cycle.

Value drivers

Revenue growth (Y1)4.0%
Terminal growth2.5%
Forecast horizon8y
Target operating margin33.0%
Years to target margin3
Sales-to-capital1.00
Beta0.85
Failure probability1.0%
Cost of capital (WACC)8.7%
Terminal WACC9.3%

Valuation bridge

PV of explicit FCFF97.76B
PV of terminal value139.79B
Equity value200.69B
÷ shares → per share$81.41

Projected free cash flow to the firm

YrRevenueGrowthMarginNOPATReinvestFCFFPV
1 70.07B 4.0% 17.7% 10.72B 2.70B 8.03B 7.38B
2 72.73B 3.8% 25.3% 15.97B 2.65B 13.31B 11.26B
3 75.32B 3.6% 33.0% 21.55B 2.60B 18.95B 14.74B
4 77.85B 3.4% 33.0% 22.27B 2.53B 19.74B 14.12B
5 80.30B 3.1% 33.0% 22.97B 2.45B 20.52B 13.50B
6 82.65B 2.9% 33.0% 23.64B 2.35B 21.29B 12.87B
7 84.89B 2.7% 33.0% 24.29B 2.24B 22.04B 12.26B
8 87.02B 2.5% 33.0% 24.89B 2.12B 22.77B 11.64B

Key risks

  • Keytruda 2028 LOE erosion outpaces subQ conversion and new launches
  • IRA price negotiation and MFN pricing pressure on key US franchises
  • Expensive M&A to fill the gap destroys value (overpaying for pipeline)

Catalysts

  • Keytruda Qlex subQ adoption rates ahead of the 2028 LOE
  • Winrevair label expansion and Phase 3 readouts from acquired assets (Cidara MK-1654 flu, Verona)

History

DatePriceIntrinsicMoSRating
2026-11-20$132.81 $81.41 -38.7% HOLD
2026-10-19$145.95 $80.49 -44.9% HOLD
2026-09-15$144.85 $18.12 -87.5% STRONG SELL
2026-08-13$132.92 $19.52 -85.3% STRONG SELL
2026-07-10$125.07 $65.41 -47.7% HOLD
2026-06-23$119.60 $68.21 -43.0% HOLD